Zogenix Unlikely to Receive Action Letter for NDA for Zohydro ER by PDUFA Goal Date of March 1, 2013

Zogenix (NASDAQ: ZGNX ), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that Zogenix is unlikely to receive an action letter for its New Drug